Document is current
Any future updates will be listed below
-
Authors
Ayala de la Peña, Francisco https://orcid.org/0000-0001-6311-920X
Martínez-Ramos, David https://orcid.org/0000-0002-6066-5763
Juan-Vidal, Oscar https://orcid.org/0000-0002-7772-9030
Gómez-Balaguer, Marcelino https://orcid.org/0000-0002-9330-6046
Miguélez, Maria https://orcid.org/0000-0002-1647-4652
Páez, David https://orcid.org/0000-0002-5596-6588
Arrazubi, Virginia https://orcid.org/0000-0002-1431-2780
Hinojo González, Carmen https://orcid.org/0000-0001-5443-7847
-
Funding
Funding for this research was provided by:
Organon (Funding of the writing of the manuscript)
Universidad de Murcia
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 30 March 2025
First Online: 18 April 2025
Declarations
:
: Francisco Ayala de la Peña has received honoraria from or acted in an advisory role for Novartis and Seagen, received funding for educational or research programmes from Daiichi Sankyo, and travel/accommodation expenses from Roche, Pfizer, Novartis, Gilead and Daiichi Sankyo. Oscar Juan-Vidal has received honoraria from or acted in an advisory role for Bristol-Myers Squibb, Roche/Genentech, AstraZeneca, Pfizer, Eli Lilly, Takeda, Janssen and Novartis, and travel/accommodation expenses from Takeda, Astra-Zeneca, Roche/Genentech, Pfizer, Merck Sharp & Dohme and Roche/Genentech. David Martínez-Ramos, Marcelino Gómez-Balaguer, Maria Miguélez, David Páez, Virginia Arrazubi and Carmen Hinojo González have no conflicts of interest.
: Ethical approval and/or obtaining informed consent is not applicable to this review article, as the research did not involve the generation or analysis of new data based on human participants and/or animals.
